摘要
[目的]观察莫沙必利联合马来酸曲美布汀对功能性消化不良的疗效。[方法]120例功能性消化不良患者随机分为A组、B组与C组,并以8例健康志愿者作为正常对照组不给任何治疗。A组予莫沙必利5mg,饭前30min,3次/d;B组予马来酸曲美布汀0.1g,3次/d;C组予莫沙必利(5mg,饭前30min,3次/d)联合马来酸曲美布汀(0.1g,3次/d);疗程均为2周。所有患者治疗前后行胃肠道症状评定量表(GSRS)的评分及胃电图检查。[结果]A、B、C组治疗前GSRS量表评分与正常对照组比较,均差异有统计学意义(P<0.05);治疗2周后,A、B、C组患者GSRS评分与治疗前相比均有下降,C组较治疗前下降明显(P<0.05)。A、B、C组治疗前空腹、餐后各胃电参数相比差异无统计学意义(P>0.05),但与正常对照组比较均差异有统计学意义(P<0.05);治疗后B、C组的胃电频率较治疗前明显减慢(P<0.05),正常慢波百分比明显增高(P<0.05);C组治疗后胃电节律紊乱百分比较治疗前显著降低(P<0.05),偶联百分比较治疗前明显增高(P<0.05)。[结论]莫沙必利联合马来酸曲美布汀治疗功能性消化不良疗效显著,且无明显不良反应发生,值得临床推广应用。
[Objective]To investigate the clinical efficacy of mosapride combined with trimebutine maleate in the treatment of functional dyspepsia.[Methods]The total of 120 patients with functional dyspepsia were randomly assigned to two-week treatments：group A mosapride 5 mg,three times a day before meals;group B,trimebutine maleate 0.1 g,three times a day;group C,mosapride in combination with trimebutine maleate.Eight healthy volunteers were served as normal controls.Score of gastrointestinal symptom rating scale（GSRS） were estimated by questionnaire.Electrogastrography（EGG）was examined before and after the treatment.[Results]After treatment,the GSRS score of C group were significantly lower than before treatment（P〈0.05）.After treatment,gastric electrical frequency of B group and C group was significantly decreased（P〈0.05）,and frequency of slow wave was increased significantly（P〈0.05）.After treatment,the percentage of gastric dysrhythmia was significantly decreased（P〈0.05）and power distribution significantly increased in C group（P〈0.05）.[Conclusion] Mosapride combined with trimebutine maleate can treat functional dyspepsia effectively with no obvious adverse reaction.
出处
《临床消化病杂志》
2017年第2期65-68,共4页
Chinese Journal of Clinical Gastroenterology
